UNASSIGNED: @entity5163 represent a major cause of global morbidity and mortality. There is an urgent need for vaccines against diarrheal pathogens, especially parasites. Modern subunit vaccines rely on combining a highly purified antigen with an adjuvant to increase their efficacy. In the present study, we evaluated the ability of a nanoliposome adjuvant system to trigger a strong mucosal immune response to the @entity2330 Gal/ @entity26243 lectin LecA antigen. CBA/J @entity19 were immunized with alum, emulsion or liposome based formulations containing synthetic TLR agonists. A liposome formulation containing TLR4 and TLR7/8 agonists was selected based on its ability to generate intestinal IgA, plasma IgG2a/IgG1, IFN-y and IL-17A. Immunization with a mucosal prime followed by a parenteral boost generated a high mucosal IgA response that inhibited adherence of parasites to @entity1 cells. Inclusion of the immune potentiator @entity1968 in the regimen further improved the mucosal IgA response. Immunization protected from infection with up to 55% efficacy. Our results show that a nanoliposome delivery system containing TLR agonists is a promising prospect for the development of vaccines against enteric pathogens, especially when a multifaceted immune response is desired.

Nanoformulation of synergistic TLR ligands to enhance vaccination against XXXX .

@entity1 :: ('9606', 'Species') :: ['mammalian'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity2330 :: ('5759', 'Species') :: ['Entamoeba histolytica'] @entity26243 :: ('CHEBI:28037', 'Chemical') :: ['GalNAc'] @entity1968 :: ('MESH:D014212', 'Chemical') :: ['all-trans retinoic acid'] @entity5163 :: ('MESH:D004403', 'Disease') :: ['Diarrheal infectious diseases']
@entity2330 :: (5759,Species) :: ['Entamoeba histolytica']
